NIBR launches new Next Generation Diagnostics (NGDx) group in Cambridge, MA.
Recruitment Underway for Personalized Cancer Dx Group
The NIBR Next Generation Diagnostics group now being recruited in Cambridge will use next generation sequencing and other cutting-edge molecular characterization technologies to discover breakthrough therapeutics, and to deliver the right medicines to the right patients.
“The NGDx team will leverage cutting-edge technologies such as next generation sequencing for characterizing human tissues, by individual lesions and by pathway signatures relevant to therapeutic response.”
Dr. William Sellers, Vice President and Global Head of Oncology at NIBR.
Learn more about this new initiative.
Read the Genome Web News Clip about initiative.
Research at NIBR
Our global research efforts begin and end with the patient.
